Insider Trades82 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Buy | NVCR | Arye Barak Ben | General Counsel | 1,299 | $11.15 | $1.8B | -27.69% | +57.94% | $14.5K | +0.54% | — | Trim |
| Jun 30, 2026 | Buy | NVCR | Frank X Leonard | Chief Executive Officer | 1,905 | $11.15 | $1.8B | -27.69% | +57.94% | $21.2K | +0.41% | — | Trim |
| Jun 30, 2026 | Buy | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,905 | $11.15 | $1.8B | -27.69% | +57.94% | $21.2K | +0.95% | — | Trim |
| Jun 4, 2026 | Sell | NVCR | Frank X Leonard | Chief Executive Officer | 34,273 | $17.93 | $1.8B | -27.69% | +57.94% | $614.6K | -6.94% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,100 | $13.31 | $1.8B | -27.69% | +57.94% | $14.6K | -0.42% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Nicolas Leupin | Former Chief Medical Officer | 1,100 | $13.31 | $1.8B | -27.69% | +57.94% | $14.6K | -1.06% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Frank X Leonard | Chief Executive Officer | 5,607 | $13.31 | $1.8B | -27.69% | +57.94% | $74.6K | -0.78% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Christoph Brackmann | Chief Financial Officer | 6,412 | $13.31 | $1.8B | -27.69% | +57.94% | $85.3K | -2.38% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Uri Weinberg | Chf Medical and Innovation Ofr | 6,412 | $13.31 | $1.8B | -27.69% | +57.94% | $85.3K | -1.85% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Ashley Cordova | Former Chief Executive Officer | 17,638 | $13.30 | $1.8B | -27.69% | +57.94% | $234.6K | -4.01% | — | Trim |
| Mar 4, 2026 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 48,623 | $13.72 | $1.8B | -27.69% | +57.94% | $667.2K | -15.63% | — | Trim |
| Mar 3, 2026 | Sell | NVCR | William F Doyle | Executive Chairman | 71,887 | $12.98 | $1.8B | -27.69% | +57.94% | $932.9K | -5.54% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Nicolas Leupin | Former Chief Medical Officer | 1,029 | $13.66 | $1.8B | -27.69% | +57.94% | $14.1K | -0.98% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,441 | $13.66 | $1.8B | -27.69% | +57.94% | $19.7K | -0.88% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 1,963 | $13.63 | $1.8B | -27.69% | +57.94% | $26.8K | -1.27% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Uri Weinberg | Chf Medical and Innovation Ofr | 10,733 | $13.68 | $1.8B | -27.69% | +57.94% | $146.9K | -2.40% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Frank X Leonard | Chief Executive Officer | 16,966 | $13.59 | $1.8B | -27.69% | +57.94% | $230.6K | -2.41% | — | Trim |
| Feb 27, 2026 | Sell | NVCR | Ashley Cordova | Former Chief Executive Officer | 21,179 | $13.71 | $1.8B | -27.69% | +57.94% | $290.4K | -1.59% | — | Trim |
| Jan 11, 2026 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 2,133 | $14.35 | $1.8B | -27.69% | +57.94% | $30.6K | -2.65% | — | Trim |
| Nov 4, 2025 | Sell | NVCR | Christoph Brackmann | Chief Financial Officer | 7,033 | $12.23 | $1.8B | -27.69% | +57.94% | $86.0K | -4.98% | — | Trim |
| Nov 1, 2025 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 966 | $12.81 | $1.8B | -27.69% | +57.94% | $12.4K | -0.28% | — | Trim |
| Nov 1, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 3,117 | $12.26 | $1.8B | -27.69% | +57.94% | $38.2K | -1.87% | — | Trim |
| Oct 31, 2025 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 752 | $12.82 | $1.8B | -27.69% | +57.94% | $9.6K | -0.46% | — | Trim |
| Sep 5, 2025 | Buy | NVCR | Ashley Cordova | Chief Executive Officer | 81,550 | $12.22 | $1.8B | -27.69% | +57.94% | $996.9K | +22.91% | — | Trim |
| Jul 29, 2025 | Buy | NVCR | Christoph Brackmann | Chief Financial Officer | 20,000 | $11.59 | $1.8B | -27.69% | +57.94% | $231.8K | +5.15% | — | Trim |
| Jun 30, 2025 | Buy | NVCR | Arye Barak Ben | General Counsel | 769 | $15.13 | $1.8B | -27.69% | +57.94% | $11.6K | +0.44% | — | Trim |
| Jun 30, 2025 | Buy | NVCR | Ashley Cordova | Chief Executive Officer | 833 | $15.13 | $1.8B | -27.69% | +57.94% | $12.6K | +0.23% | — | Trim |
| Jun 30, 2025 | Buy | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 833 | $15.13 | $1.8B | -27.69% | +57.94% | $12.6K | +0.24% | — | Trim |
| Jun 30, 2025 | Buy | NVCR | Michal Nath Puri | Chief Human Resources Officer | 833 | $15.13 | $1.8B | -27.69% | +57.94% | $12.6K | +0.51% | — | Trim |
| Jun 2, 2025 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 30,196 | $17.50 | $1.8B | -27.69% | +57.94% | $528.4K | -5.53% | — | Trim |
| May 3, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 592 | $17.91 | $1.8B | -27.69% | +57.94% | $10.6K | -0.70% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Mukund Paravasthu | Chief Operating Officer | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +49.67% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +24.41% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Uri Weinberg | Chief Innovation Officer | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +22.19% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Michal Nath Puri | Chief Human Resources Officer | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +28.90% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Arye Barak Ben | General Counsel | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +27.46% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Nicolas Leupin | Chief Medical Officer | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +41.76% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Christoph Brackmann | Chief Financial Officer | 54,975 | $18.19 | $1.8B | -27.69% | +57.94% | $1.0M | +37.23% | — | Trim |
| Mar 4, 2025 | Buy | NVCR | Ashley Cordova | Chief Executive Officer | 151,181 | $18.19 | $1.8B | -27.69% | +57.94% | $2.7M | +35.31% | — | Trim |
| Mar 3, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 250 | $18.54 | $1.8B | -27.69% | +57.94% | $4.6K | -0.85% | — | Trim |
| Mar 3, 2025 | Sell | NVCR | Uri Weinberg | Chief Innovation Officer | 268 | $18.92 | $1.8B | -27.69% | +57.94% | $5.1K | -0.16% | — | Trim |
| Mar 3, 2025 | Sell | NVCR | Ashley Cordova | Chief Executive Officer | 2,053 | $18.54 | $1.8B | -27.69% | +57.94% | $38.1K | -1.00% | — | Trim |
| Mar 3, 2025 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 2,527 | $18.54 | $1.8B | -27.69% | +57.94% | $46.8K | -1.73% | — | Trim |
| Feb 28, 2025 | Sell | NVCR | Uri Weinberg | Chief Innovation Officer | 4,637 | $18.75 | $1.8B | -27.69% | +57.94% | $86.9K | -1.37% | — | Trim |
| Feb 28, 2025 | Sell | NVCR | Uri Weinberg | Chief Innovation Officer | 4,637 | $18.75 | $1.8B | -27.69% | +57.94% | $86.9K | -1.37% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Nicolas Leupin | Chief Medical Officer | 991 | $20.02 | $1.8B | -27.69% | +57.94% | $19.8K | -0.98% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Nicolas Leupin | Chief Medical Officer | 991 | $20.02 | $1.8B | -27.69% | +57.94% | $19.8K | -0.98% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,387 | $20.02 | $1.8B | -27.69% | +57.94% | $27.8K | -0.63% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,387 | $20.02 | $1.8B | -27.69% | +57.94% | $27.8K | -0.63% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 2,014 | $19.71 | $1.8B | -27.69% | +57.94% | $39.7K | -2.21% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 2,014 | $19.71 | $1.8B | -27.69% | +57.94% | $39.7K | -2.21% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Ashley Cordova | Chief Executive Officer | 13,494 | $19.72 | $1.8B | -27.69% | +57.94% | $266.1K | -2.11% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Ashley Cordova | Chief Executive Officer | 13,494 | $19.72 | $1.8B | -27.69% | +57.94% | $266.1K | -2.11% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 15,036 | $19.70 | $1.8B | -27.69% | +57.94% | $296.3K | -3.26% | — | Trim |
| Feb 27, 2025 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 15,036 | $19.70 | $1.8B | -27.69% | +57.94% | $296.3K | -3.26% | — | Trim |
| Jan 11, 2025 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 2,160 | $26.81 | $1.8B | -27.69% | +57.94% | $57.9K | -6.43% | — | Trim |
| Dec 31, 2024 | Buy | NVCR | Ashley Cordova | Chief Executive Officer | 373 | $14.75 | $1.8B | -27.69% | +57.94% | $5.5K | +0.17% | — | Trim |
| Dec 31, 2024 | Buy | NVCR | Arye Barak Ben | General Counsel | 669 | $14.75 | $1.8B | -27.69% | +57.94% | $9.9K | +0.57% | — | Trim |
| Nov 2, 2024 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 44 | $16.69 | $1.8B | -27.69% | +57.94% | $734.175 | -0.09% | — | Trim |
| Nov 1, 2024 | Sell | NVCR | Mukund Paravasthu | Chief Operating Officer | 160 | $15.88 | $1.8B | -27.69% | +57.94% | $2.5K | -4.37% | — | Trim |
| Nov 1, 2024 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 598 | $15.94 | $1.8B | -27.69% | +57.94% | $9.5K | -0.37% | — | Trim |
| Oct 31, 2024 | Sell | NVCR | Michal Nath Puri | Chief Human Resources Officer | 810 | $15.79 | $1.8B | -27.69% | +57.94% | $12.8K | -0.73% | — | Trim |
| Aug 2, 2024 | Sell | NVCR | Ashley Cordova | Chief Financial Officer | 688 | $20.14 | $1.8B | -27.69% | +57.94% | $13.9K | -0.31% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Arye Barak Ben | General Counsel | 930 | $12.24 | $1.8B | -27.69% | +57.94% | $11.4K | +0.79% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Wilhelmus Cm Groenhuysen | Chief Operating Officer | 1,055 | $12.24 | $1.8B | -27.69% | +57.94% | $12.9K | +0.42% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Asaf Danziger | Chief Executive Officer | 1,239 | $12.24 | $1.8B | -27.69% | +57.94% | $15.2K | +8.86% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Ashley Cordova | Chief Financial Officer | 1,286 | $12.24 | $1.8B | -27.69% | +57.94% | $15.7K | +0.59% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Michal Nath Puri | Chief Human Resources Officer | 1,736 | $12.24 | $1.8B | -27.69% | +57.94% | $21.2K | +1.59% | — | Trim |
| Jun 28, 2024 | Buy | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 1,736 | $12.24 | $1.8B | -27.69% | +57.94% | $21.2K | +1.08% | — | Trim |
| Jun 5, 2024 | Buy | NVCR | Wilhelmus Cm Groenhuysen | Chief Operating Officer | 124,373 | $22.82 | $1.8B | -27.69% | +57.94% | $2.8M | +130.92% | — | Trim |
| Mar 1, 2024 | Sell | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 2,519 | $16.02 | $1.8B | -27.69% | +57.94% | $40.4K | -0.78% | — | Trim |
| Mar 1, 2024 | Sell | NVCR | Wilhelmus Cm Groenhuysen | Chief Operating Officer | 3,324 | $16.02 | $1.8B | -27.69% | +57.94% | $53.3K | -0.66% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Moshe Giladi | Chief Science Officer | 51,124 | $16.30 | $1.8B | -27.69% | +57.94% | $833.3K | +52.80% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Nicolas Leupin | Chief Medical Officer | 51,124 | $16.30 | $1.8B | -27.69% | +57.94% | $833.3K | +65.40% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Michal Nath Puri | Chief Human Resources Officer | 71,574 | $16.30 | $1.8B | -27.69% | +57.94% | $1.2M | +48.68% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Uri Weinberg | Chief Innovation Officer | 81,799 | $16.30 | $1.8B | -27.69% | +57.94% | $1.3M | +38.15% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Ashley Cordova | Chief Financial Officer | 102,249 | $16.30 | $1.8B | -27.69% | +57.94% | $1.7M | +37.32% | — | Trim |
| Feb 27, 2024 | Buy | NVCR | Frank X Leonard | EVP, Pres., Novocure Oncology | 104,327 | $16.30 | $1.8B | -27.69% | +57.94% | $1.7M | +26.12% | — | Trim |
| Dec 31, 2023 | Buy | NVCR | Wilhelmus Cm Groenhuysen | Chief Operating Officer | 49,340 | $16.29 | $1.8B | -27.69% | +57.94% | $803.9K | +5.98% | — | Trim |
| Dec 31, 2023 | Buy | NVCR | Arye Barak Ben | General Counsel | 81,927 | $16.29 | $1.8B | -27.69% | +57.94% | $1.3M | +41.89% | — | Trim |
| Nov 7, 2023 | Sell | NVCR | Pritesh Shah | Chief Growth Officer | 382 | $12.65 | $1.8B | -27.69% | +57.94% | $4.8K | -0.31% | — | Trim |
| Oct 31, 2023 | Buy | NVCR | Ashley Cordova | Chief Financial Officer | 17,968 | $9.60 | $1.8B | -27.69% | +57.94% | $172.5K | +4.14% | — | Trim |